Replies to post #430635 on Amarin Corp Plc (AMRN)

[rosemountbomber]

We are always last to know. If there was really great news about to surface sp wouldn't be sinking. All these medical establishments approve V but no one wants to pay for it. Of course, as many believe, in the hands of BP these reimbursements would have gone differently. But that is water under the bridge as this should have been sold right at R-I release.

[Chromosome]

While I wasn’t expecting NRDL approval this year (although hoping) because of the tight deadline (although technically they got approved a couple of days before the July 1st deadline), I don’t think anyone knows unless the list gets published sometime this month. As far as future prospects, not sure logically how anyone could know unless they are on the NRDL decision making committee. Just my opinion.

[seve333]

Would not shock me in the least with the way things have gone with AMRN. Company should have been sold long ago and now it is on life support.

[Birdbrain Ideas]

Then a real loser in that scenario is Edding, which just forked over $15 million to Amarin. I'd be bummed out if I was them. I think Amarin is really banking on Europe and the rest of the world anyway. They seem to only mention China in passing, perhaps because they knew this was an unreliable prospect. So if the share droop is because of this, it sounds like a buying opportunity.

[Denisk]

Thanks. I saw that post from BioForGood, but this was questioned as not being true from another poster (San Diego living), Notwithstanding his post, BioForGood, also said he was not about to sell his shares at such a depressed share price. Also another poster (Bob Good) posted the following:
"Thank you @BioForGood for valuable info..
But, I am still optimistic. Why?
Three main routes to market in China: private, out-of-pocket/patient assistance schemes & public reimbursement.
Out-of-pocket/patient have typically been the first route by manufactures, and with a rising middle class, this route presents a sizeable 30% opportunity..
Via NRDL means fully or partially reimbursed at a national level in public hospitals. Historically such drugs were generics.. may be good for Vazkepa after AG in US?
More opportunity via NRDL for access has it's own drawbacks. China has made strikingly high demands, sometimes asking for discounts as high as 90% !!! But this negates having to also reduce prices in other countries which may quote China!!
So, I am still hopeful for out of packet route for $AMRN. Why? Because, even if Vazkepa captures 1% of China’s CVD market (330M) could generate > $3B.
GL Longs.
I will post the relevant link from which I collected the above info..
Bullish
BioForGood
Yesterday 8:00 PM"
So based on the above, who are we to believe... without any public confirmation all of these news seem unconfirmed so far?